ClinicalTrials.gg
CompletedNCT00284089Updated Feb 24, 2011Results posted

Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

A Phase 1/2 interventional study of Ranibizumab in Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD), sponsored by Novartis. Completed at 1 site in Japan. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-02-24.

Sponsored by Novartis · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
20th of 45
88 · median 62
Started
2005
with 3 others
Phase 1/2
4 of 45
none open now
Registered
2nd of 45
by date
Lead sponsor
5 of 45
Novartis

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 20th largest by enrollment, is one of 4 that started in 2005, is one of 4 in phase 1/2, and was the 2nd registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

Open-label Multicenter, Phase I/II Study comprising three phases (single dose, multiple dose and extension phase), Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD).

Read the detailed description

The safety and tolerability of single intravitreal injections of ranibizumab was evaluated in patients enrolled in the single dose phase (Group A). Patients who successfully completed the single dose phase (i.e. did not experience a grade-3 targeted adverse event) could enter the multiple dose phase and receive ranibizumab injections for an additional 11 months. Simultaneously, the multiple dose phase was initiated in two parallel dose groups of additional patients (Group B), who received ranibizumab injections for 12 months. After patients in Group A and Group B had completed the multiple dose phase, all patients who provided written consent and were considered eligible based on the inclusion and exclusion criteria of the extension phase had the opportunity to continue on study treatment with the individualized flexible treatment regimen guided by monthly acuity scores and other ophthalmic examinations until approval of ranibizumab in Japan.

03

Conditions studied

  • Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD)

Keywords

  • Subfoveal CNV, AMD, ranibizumab
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria

  1. Male or female patients 50 years of age or greater
  2. Patients with primary or recurrent subfoveal CNV secondary to AMD
  3. Patients who have a BCVA score between 73 and 24 letters in the study eye using ETDRS-like grading charts (approximately 20/40 to 20/320)

Exclusion Criteria

  1. No prior treatment in the study eye with verteporfin, external-beam radiation therapy, subfoveal focal laser photocoagulation, vitrectomy, or transpupillary thermotherapy

Extension Phase

Inclusion criteria:

  1. Personally provided written to participate in the extension phase.
  2. Patients with subfoveal CNV secondary to AMD who had completed the multiple dose phase in either of the ranibizumab groups (Group A or B).
  3. Patients could participate in the extension phase even if they failed to do so on the day of the exit visit in the multiple dose phase (Group A and B), regardless of the time elapsed until the participation in the extension phase.

Exclusion criteria:

  1. Received anti-angiogenic drugs (bevacizumab, pegaptanib, ranibizumab, anecortave acetate, or protein kinase C inhibitors, etc.) or
  2. Participated in any clinical study of an drug other than this one during the period between the exit visit of the multiple dose phase and the start in the extension phase, if they failed to be enrolled into the extension on the day of the exit visit. Patients were to be excluded even when the fellow eye was treated with any of these drugs.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Group A: Ranibizumab 0.3 mg

    In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.3 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.3 mg of ranibizumab once a month for an additional 11 months. Subsequently patients enrolling in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.70 years.

    Drug: Ranibizumab

  • Experimental
    Group A: Ranibizumab 0.5 mg

    In the single dose phase, all patients randomized in Group A received a single intravitreal injection of 0.5 mg of ranibizumab into the study eye. Those patients who successfully completed this phase entered the multiple dose phase, where they received an intravitreal injection of 0.5 mg of ranibizumab once a month for an additional 11 months. Subsequently Group A patients enrolling in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.93 years.

    Drug: Ranibizumab

  • Experimental
    Group B: Ranibizumab 0.3 mg

    Group B patients received a total of 12 monthly intravitreal injections of 0.3 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.3 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.45 years.

    Drug: Ranibizumab

  • Experimental
    Group B: Ranibizumab 0.5 mg

    Group B patients received a total of 12 monthly intravitreal injections of 0.5 mg of ranibizumab into the study eye in the multiple dose phase of the study. Group B patients who enrolled in the extension phase received an intravitreal injection of 0.5 mg of ranibizumab according to an individualized flexible interval regimen guided by monthly best corrected visual acuity scores and other ophthalmic examinations. In the extension phase patients received the same dose level as they received in the multiple dose phase of the study, for an average of 1.36 years.

    Drug: Ranibizumab

Interventions

  • Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.

    Also known as: Lucentis

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B

    The efficacy assessment was based on Group B patients. Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

    Time frame: Baseline and Month 6

Secondary outcomes

  1. Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 12 in Group B

    The efficacy assessment was based on Group B patients. BCVA was assessed during all study visits using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

    Time frame: Baseline and Month 12

  2. Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Month 6 and Month 12 in Group B

    BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters.

    Time frame: Baseline, Month 6 and Month 12

  3. Extension Phase: Mean Change From Month 12 (Start of Extension Phase) in Best Corrected Visual Acuity Score of the Study Eye at Last Visit of Extension Phase in Group B.

    Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

    Time frame: Month 12 (start of extension phase) and last visit of extension phase. Duration in the extension phase varied depending on the study entry. The mean duration of treatment was 1.45 years in the 0.3 mg group and 1.36 years in the 0.5 mg dose group.

  4. Extension Phase: Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Last Visit of Extension Phase in Group B

    BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The following categories were evaluated: * Participants with a BCVA score loss of fewer than 15 letters from baseline at Last Visit * Participants with a BCVA score loss of 30 or more letters from baseline at Last Visit * Participants with a BCVA score gain of 15 or more letters from baseline at Last Visit * Participants with a BCVA score of less than 34 letters at Last Visit

    Time frame: Baseline and last visit of extension phase - Duration in the extension phase varied depending on the study entry. The mean duration of treatment was 1.45 years in the 0.3 mg group and 1.36 years in the 0.5 mg dose group.

  5. Mean Change From Baseline in Total Area of Choroidal Neovascularization of the Study Eye in Group B

    Choroidal Neovascularization was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The area of Choroidal Neovascularization is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).

    Time frame: Baseline, Months 3, 6, 9 and 12

  6. Mean Change From Baseline in Total Area of Leakage From CNV Plus Staining of Retinal Pigment Epithelium of the Study Eye in Group B

    Area of leakage from CNV plus staining of retinal pigment epithelium was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The total area is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).

    Time frame: Baseline, Months 3, 6, 9 and 12

  7. Percentage of Participants in Group B With Absence of Leakage in the Study Eye at Month 3, 6, 9 and 12.

    Area of leakage was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed at the central reading center.

    Time frame: Months 3, 6, 9 and 12

  8. Mean Change From Baseline in Foveal Retinal Thickness of the Study Eye in Group B

    Foveal retinal thickness was assessed by Optical Coherence Tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.

    Time frame: Baseline, Months 3, 6, 9 and 12

  9. Mean Change From Baseline in Total Retinal Volume of the Study Eye in Group B

    Total retinal volume was assessed by Optical Coherence tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.

    Time frame: Baseline, Months 3, 6, 9 and 12

07

Results

Posted Feb 11, 2011

Participant flow

Single Dose Phase
Participant flow — Single Dose Phase
MilestoneGroup A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Started6600
Completed6600
Not completed0000
Multiple Dose Phase
Participant flow — Multiple Dose Phase
MilestoneGroup A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Started563541
Completed463137
Not completed1044
Withdrew: Adverse event1011
Withdrew: Protocol violation0010
Withdrew: Withdrawal by subject0012
Withdrew: Death0011
Extension Phase
Participant flow — Extension Phase
MilestoneGroup A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Started362833
Completed162221
Not completed20612
Withdrew: Adverse event0022
Withdrew: Condition no longer requires study drug2027
Withdrew: Protocol violation0010
Withdrew: Withdrawal by subject0013

Outcome measures

PrimaryMean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B

The efficacy assessment was based on Group B patients. Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

Time frame:
Baseline and Month 6
Reported as:
Mean · Number of Letters
Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 6 in Group B
Number of LettersGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline47.6 ± 11.8248.1 ± 10.75
Month 655.7 ± 13.1657.1 ± 14.99
Change from Baseline8.1 ± 12.659.0 ± 9.62
SecondaryMean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 12 in Group B

The efficacy assessment was based on Group B patients. BCVA was assessed during all study visits using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

Time frame:
Baseline and Month 12
Reported as:
Mean · Number of Letters
Mean Change From Baseline in the Best Corrected Visual Acuity Score of the Study Eye at Month 12 in Group B
Number of LettersGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline47.6 ± 11.8248.1 ± 10.75
Month 1257.1 ± 12.9158.6 ± 15.44
Change from Baseline9.5 ± 12.7910.5 ± 11.14
SecondaryCategorical Analysis of Best Corrected Visual Acuity of the Study Eye at Month 6 and Month 12 in Group B

BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters.

Time frame:
Baseline, Month 6 and Month 12
Reported as:
Number · Participants
Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Month 6 and Month 12 in Group B
ParticipantsGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Loss of < 15 letters from Baseline at month 63441
Loss of < 15 letters from Baseline at month 123441
Gain of ≥15 letters from Baseline at month 61210
Gain of ≥15 letters from Baseline at month 121313
Loss of ≥30 letters from Baseline at month 600
Loss of ≥30 letters from Baseline at month 1200
Visual acuity < 34 letters at Month 622
Visual acuity < 34 letters at Month 1221
SecondaryExtension Phase: Mean Change From Month 12 (Start of Extension Phase) in Best Corrected Visual Acuity Score of the Study Eye at Last Visit of Extension Phase in Group B.

Best Corrected Visual Acuity (BCVA) was assessed during all study visits using best correction determined from protocol refraction at a starting test distance of 2 meters. VA measurements were taken in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a starting test distance of 2 meters. The BCVA score is the number of letters read correctly by the patient, hence an increase in score indicates improvement in acuity.

Time frame:
Month 12 (start of extension phase) and last visit of extension phase. Duration in the extension phase varied depending on the study entry. The mean duration of treatment was 1.45 years in the 0.3 mg group and 1.36 years in the 0.5 mg dose group.
Reported as:
Mean · Letters
Extension Phase: Mean Change From Month 12 (Start of Extension Phase) in Best Corrected Visual Acuity Score of the Study Eye at Last Visit of Extension Phase in Group B.
LettersGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline47.9 ± 12.5950.0 ± 10.38
Month 1259.1 ± 11.6959.8 ± 15.07
Last visit55.4 ± 17.1457.6 ± 15.36
Change from Month 12-3.6 ± 14.82-2.2 ± 7.92
SecondaryExtension Phase: Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Last Visit of Extension Phase in Group B

BCVA measurements were taken in a sitting position using best correction determined from protocol refraction and ETDRS-like visual acuity testing charts at a starting test distance of 2 meters. The following categories were evaluated: * Participants with a BCVA score loss of fewer than 15 letters from baseline at Last Visit * Participants with a BCVA score loss of 30 or more letters from baseline at Last Visit * Participants with a BCVA score gain of 15 or more letters from baseline at Last Visit * Participants with a BCVA score of less than 34 letters at Last Visit

Time frame:
Baseline and last visit of extension phase - Duration in the extension phase varied depending on the study entry. The mean duration of treatment was 1.45 years in the 0.3 mg group and 1.36 years in the 0.5 mg dose group.
Reported as:
Number · Participants
Extension Phase: Categorical Analysis of Best Corrected Visual Acuity of the Study Eye at Last Visit of Extension Phase in Group B
ParticipantsGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Loss of < 15 letters from Baseline2432
Gain of ≥15 letters from Baseline99
Loss of ≥30 letters from Baseline11
Visual acuity < 34 letters31
SecondaryMean Change From Baseline in Total Area of Choroidal Neovascularization of the Study Eye in Group B

Choroidal Neovascularization was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The area of Choroidal Neovascularization is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).

Time frame:
Baseline, Months 3, 6, 9 and 12
Reported as:
Mean · disc areas
Mean Change From Baseline in Total Area of Choroidal Neovascularization of the Study Eye in Group B
disc areasGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline [N=35, 41]2.11 ± 1.102.03 ± 1.66
Mean change from Baseline at Month 3 [N=34, 40]-0.10 ± 0.950.13 ± 0.75
Mean change from Baseline at Month 6 [N=34, 40]-0.15 ± 0.970.04 ± 0.76
Mean change from Baseline at Month 9 [N=34, 40]-0.23 ± 0.970.21 ± 0.90
Mean change from Baseline at Month 12 [N=34, 40]-0.16 ± 1.010.23 ± 1.08
SecondaryMean Change From Baseline in Total Area of Leakage From CNV Plus Staining of Retinal Pigment Epithelium of the Study Eye in Group B

Area of leakage from CNV plus staining of retinal pigment epithelium was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed by the central reading center. The total area is expressed as Macular Photocoagulation Study standard Disc Areas (DA; equivalent to 2.54 mm\^2 on the retina).

Time frame:
Baseline, Months 3, 6, 9 and 12
Reported as:
Mean · disc areas
Mean Change From Baseline in Total Area of Leakage From CNV Plus Staining of Retinal Pigment Epithelium of the Study Eye in Group B
disc areasGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline [N=35, 41]2.31 ± 1.172.49 ± 1.54
Mean change from Baseline at Month 3 [N=34, 40]-0.76 ± 0.85-0.74 ± 1.21
Mean change from Baseline at Month 6 [N=34, 40]-1.21 ± 0.87-1.10 ± 1.19
Mean change from Baseline at Month 9 [N=34, 40]-1.39 ± 1.02-1.26 ± 1.45
Mean change from Baseline at Month 12 [N=34, 40]-1.50 ± 1.08-1.39 ± 1.48
SecondaryPercentage of Participants in Group B With Absence of Leakage in the Study Eye at Month 3, 6, 9 and 12.

Area of leakage was assessed by fluorescein angiography in conjunction with color fundus photography. Analysis was performed at the central reading center.

Time frame:
Months 3, 6, 9 and 12
Reported as:
Number · Percentage of participants
Percentage of Participants in Group B With Absence of Leakage in the Study Eye at Month 3, 6, 9 and 12.
Percentage of participantsGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Month 32.97.5
Month 68.815.0
Month 926.525.0
Month 1235.335.0
SecondaryMean Change From Baseline in Foveal Retinal Thickness of the Study Eye in Group B

Foveal retinal thickness was assessed by Optical Coherence Tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.

Time frame:
Baseline, Months 3, 6, 9 and 12
Reported as:
Mean · micrometers
Mean Change From Baseline in Foveal Retinal Thickness of the Study Eye in Group B
micrometersGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline [N=28, 30]336.7 ± 195.3370.7 ± 171.9
Mean change from Baseline at Month 3 [N=27, 29]-124.4 ± 141.6-195.6 ± 187.5
Mean change from Baseline at Month 6 [N=26, 28]-142.9 ± 199.3-225.6 ± 192.2
Mean change from Baseline at Month 9 [N=26, 27]-188.4 ± 190.1-245.4 ± 203.1
Mean change from Baseline at Month 12 [N=26, 26]-194.0 ± 199.8-257.8 ± 209.8
SecondaryMean Change From Baseline in Total Retinal Volume of the Study Eye in Group B

Total retinal volume was assessed by Optical Coherence tomography (OCT) at a subset of the study sites and was analyzed by the central reading center.

Time frame:
Baseline, Months 3, 6, 9 and 12
Reported as:
Mean · micrometers
Mean Change From Baseline in Total Retinal Volume of the Study Eye in Group B
micrometersGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mg
Baseline [N=11, 11]7.23 ± 0.847.36 ± 0.97
Mean change from Baseline at Month 3 [N=7, 7]-0.78 ± 0.74-0.67 ± 0.71
Mean change from Baseline at Month 6 [N=6, 6]-0.52 ± 0.60-0.92 ± 0.96
Mean change from Baseline at Month 9 [N=4, 5]-0.48 ± 0.03-0.28 ± 0.83
Mean change from Baseline at Month 12 [N=6, 6]-0.95 ± 1.14-0.42 ± 0.67

Adverse events

Collected over The timeframe for the Core Phase (Single and Multiple Dose Phases) was 12 months. For the Extension Phase adverse event data was collected from Month 12 through to the Last Visit (the maximum time on study was 35 months total).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Core Group A+B: Ranibizumab 0.3 mg—5/41 (12.2%)38/41 (92.7%)
Core Group A+B: Ranibizumab 0.5 mg—8/47 (17%)43/47 (91.5%)
Extension Group A+B: Ranibizumab 0.3 mg—5/31 (16.1%)27/31 (87.1%)
Extension Group A+B: Ranibizumab 0.5 mg—8/39 (20.5%)28/39 (71.8%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCore Group A+B: Ranibizumab 0.3 mgCore Group A+B: Ranibizumab 0.5 mgExtension Group A+B: Ranibizumab 0.3 mgExtension Group A+B: Ranibizumab 0.5 mg
Visual acuity reduced transiently (Study eye)Eye disorders0/412/470/310/39
Overdose (Study eye)Injury, poisoning and procedural complications0/412/470/310/39
Intraocular pressure increased (Study eye)Investigations0/412/470/310/39
Glaucomatocyclitic crises (Study eye)Eye disorders0/410/471/310/39
Macular degeneration (Study eye)Eye disorders0/410/471/310/39
Retinal detachment (Study eye)Eye disorders0/410/471/310/39
Vitreous haemorrhage (Study eye)Eye disorders0/410/471/310/39
EnteroceleGastrointestinal disorders0/410/471/310/39
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/410/471/310/39
Cerebral infarctionNervous system disorders0/410/471/311/39
Most frequent other events
Showing 10 of 29
Most frequent other events
EventCore Group A+B: Ranibizumab 0.3 mgCore Group A+B: Ranibizumab 0.5 mgExtension Group A+B: Ranibizumab 0.3 mgExtension Group A+B: Ranibizumab 0.5 mg
Conjunctival haemorrhage (Study eye)Eye disorders30/4128/4713/3114/39
Retinal haemorrhage (Study eye)Eye disorders12/415/479/3110/39
NasopharyngitisInfections and infestations7/4110/476/319/39
Eye pain (Study eye)Eye disorders9/4110/472/310/39
Conjunctival hyperaemia (Study eye)Eye disorders8/418/472/311/39
Retinal haemorrhage (Fellow eye)Eye disorders3/415/476/312/39
Punctate keratitis (Study eye)Eye disorders7/414/471/311/39
HypertensionVascular disorders3/411/474/311/39
Retinal detachment (Study eye)Eye disorders5/412/472/315/39
Intraocular pressure increased (Study eye)Investigations2/416/472/314/39

Baseline characteristics

Age, Customized
Age, Customized(Participants)Group A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mgTotal
50 to <65 years2081020
65 to <75 years24161335
75 to <85 years22101529
>= 85 years00134
Age, Customized
Age, Customized(Participants)Group A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mgTotal
50 to <65 years1071018
65 to <75 years14141029
75 to <85 years1261221
>= 85 years00112
Sex: Female, Male
Sex: Female, Male(Participants)Group A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mgTotal
Female119819
Male55263369
Gender
Gender(participants)Group A: Ranibizumab 0.3 mgGroup A: Ranibizumab 0.5 mgGroup B: Ranibizumab 0.3 mgGroup B: Ranibizumab 0.5 mgTotal
Female019515
Male35192855
08

Study locations

1 site
  • Novartis
    Tokyo, Japan
09

References and documents

Publications

  • Tano Y, Ohji M; EXTEND-I Study Group. EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol. 2010 May;88(3):309-16. doi: 10.1111/j.1755-3768.2009.01843.x. Epub 2010 Feb 16. PubMed 20163368 ↗
  • Tano Y, Ohji M; EXTEND-I Study Group. Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study. Acta Ophthalmol. 2011 May;89(3):208-17. doi: 10.1111/j.1755-3768.2010.02065.x. Epub 2011 Jan 14. PubMed 21232078 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005, a primary completion of Mar 2007 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2006
First posted
Jan 31, 2006
Start
Apr 2005
Primary completionActual
Mar 2007
CompletionActual
Jan 2009
Results first posted
Feb 11, 2011
Last update
Feb 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00284089
Lead sponsor
Novartis
First posted
Jan 31, 2006
Start date
Apr 2005
Primary completion
Mar 2007
Completion
Jan 2009
Results posted
Feb 11, 2011
Last update
Feb 24, 2011

Study contacts

Novartis Customer Information
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion